* The Abstract should be related to the program objectives and not exceeding 250 words.
* Submissions must be postmarked no later than **3rd FEBRUARY, 2022.**
* Submissions will be reviewed by the Scientific Committee and you will be notified if your entry has been selected by **5th February, 2022.**
* Please retain a copy for your records. In acceptance of the Abstract, fully completed manuscript should be emailed to (maica[@menaconference.com](mailto:afsal.ahmad@menaconf.com))

**ORAL PRESENTATION:** limited to clinical research/study, quality project or audit and case report/case series

|  |  |
| --- | --- |
| **Complete Name**  **(Lead Author/Presenting Author)** |  |
| **Profession/Designation:** |  |
| **Place of Work/Affiliation:** |  |
| **Qualifications:** |  |
| **Current Area of Practice:** |  |
| **Mobile:** |  |
| **Email:** |  |

All abstracts must be prepared using the abstract submission guidelines (please see separate document)

Authors affiliations, abstracts title and references will not form part of the abstract document but should be indicated in separate fields during the abstract submission.

**Abstract Structure:**

* Title
* Affiliation
* Abstract Text:

**A: Clinical research/ study:**

1. Introduction or background, (2) Objectives, (3) Methods, (4) Results, (5) Discussions and (6) Conclusions

**B: Quality project or audit:**

1. Introduction or background, (2) Objectives, (3) Methods, (4) Results, (5) Discussions and (6) Conclusions

**C: Case report or Case series:**

(1) Introduction or background, (2) Objectives, (3) Clinical Case (including

diagnostic evaluation, treatment, and follow‐up) and(4)Conclusion(s)

* References
* Maximum Word count – **250 words**
  + Please provide an accurate, succinct, and informative summary of the content. Be concise.
  + Type abstract using font type (Arial), font size (12pt) and 1½ line spacing.
  + Use A4 size paper
* **Authors are advised to get authorisation from their relevant department or Chief or Academic department**
* **Please keep in mind that the scientific committee will make the final decision on accepting submissions.**
* **Incomplete submissions will not be considered for review**

**A: Clinical research/ study**

**Title:** \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**Affiliation:** \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**Abstract Text:**

1. Introduction or background
2. Objectives
3. Methods
4. Results
5. Discussion
6. Conclusion(s)
7. References

**B: Quality project or audits**

**Title:** \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**Affiliation:** \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**Abstract Text:**

1. Introduction or background
2. Objectives
3. Methods
4. Results
5. Discussion
6. Conclusion(s)
7. References

**C: Case report or Case series**

**Title:** *The title of the abstract should emphasize the clinical condition and main teaching point*

**Affiliation: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

**Abstract Text:**

1. Introduction or background
2. Objectives
3. Clinical Case (including history, physical findinsgs, diagnostic evaluation, treatment, and follow‐up)
   1. For laboratory parameters, the units of measurement and normal ranges must be provided.
   2. Statements about ongoing studies or pending results should be avoided.
4. Conclusion(s): should emphasize the learning point(s) and implications for clinical practice.
5. References

Kindly submit your abstract to Ms. Maica via email ([maica@menaconference.com](mailto:maica@menaconference.com))

For any further information, please contact Ms. Maica +971 2 4919888

Mobile: +971 50 297 6822

# Thank you for your interest to present at the

# ****3rd Emirates Pediatric Endocrine Conference****